Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen: results of a double-blind randomised phase III trial
- 30 September 2000
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 36, 86-87
- https://doi.org/10.1016/s0959-8049(00)00240-9
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Aromatase inhibitors in advanced breast cancerSeminars in Oncology, 2004
- Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinomaCancer, 1998
- Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implicationsThe Journal of Steroid Biochemistry and Molecular Biology, 1998
- Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.Journal of Clinical Oncology, 1998